Options
Lipoxins : regulators of resolution
Author(s)
Date Issued
2010-04
Date Available
2010-08-19T14:22:41Z
Abstract
Persistent inflammation underlies many of the most prevalent diseases in the developed world including atherosclerosis and diabetes. There is a growing appreciation that inflammation and its active resolution may be modulated by endogenously produced lipid mediators. Preeminent amongst these mediators are the lipoxins [LX]. The acronym lipoxin describes the provenance of these mediators: lipoxygenase interacting products . The LX are eicosanoids and display both anti-inflammatory and pro-resolving bioactions. More recently other pro-resolving lipid mediators have been described including the resolvins and neuroprotectins. In effective host defence LX biosynthesis is characterised by a switch from pro-inflammatory prostaglandin and leukotriene (LT) generation from arachidonic acid (AA) to LX production coincident with a return to tissue homeostasis ( see figure 1). Here we will provide an overview of LX pharmacokinetics, bioactions and summarise the evidence to date that indicates that LX are potential therapeutic agents for disorders involving cardiovascular and renal inflammation, leading to tissue damage and organ fibrosis.
Sponsorship
Science Foundation Ireland
Higher Education Authority
Other Sponsorship
Wellcome trust
Health Research Board
Type of Material
Journal Article
Publisher
Elsevier
Journal
Current Opinion in Pharmacology
Volume
10
Issue
2
Start Page
166
End Page
172
Copyright (Published Version)
Copyright 2010 Elsevier Ltd
Subject – LCSH
Lipoxins--Therapeutic use
Inflammation--Mediators
Lipoxins--Pharmacokinetics
Web versions
Language
English
Status of Item
Peer reviewed
ISSN
1471-4892
This item is made available under a Creative Commons License
File(s)
Owning collection
Scopus© citations
77
Acquisition Date
Apr 16, 2024
Apr 16, 2024
Views
1978
Last Week
2
2
Last Month
3
3
Acquisition Date
Apr 16, 2024
Apr 16, 2024
Downloads
975
Last Week
2
2
Last Month
17
17
Acquisition Date
Apr 16, 2024
Apr 16, 2024